ThermoGenesis Holdings, Inc. · OTC:THMO

ThermoGenesis — Investor Presentation (June 2011)

18 slides from ThermoGenesis's investor presentation, June 2011

  1. Slide 1: Investor Presentation June 2011

    Investor Presentation June 2011

  2. Slide 2: Safe Harbor

    Safe Harbor Certain matters discussed in this presentation are "forward-looking statements." These forward- looking statements can generally be identified as by the context of the statement that includes words such as the Company "expects," "anticipates" or words of similar import. Similarly, statem

  3. Slide 3: KOOL Strategic Overview

    KOOL Strategic Overview • Who we are: Enabling technology provider for the automation of cell processing, storage and administration (in the lab and at the point of care): • Commercialization pathways: – First ‐ Existing products into a new geography and territories – Second‐ Line extensions for new

  4. Slide 4: Key Highlights

    Key Highlights ($ in millions) ($ in millions) 4

  5. Slide 5: Compelling Story

    Compelling Story (1) Rodman & Renshaw China Cord Corp. initiation report February 18, 2010 (2) Cord blood market opportunity assumes newborn population of 7 million in urban areas, $730 initiation fee, $73 annual storage fee, and average storage contract length of 18 years present value adjusted at

  6. Slide 6: The Worldwide Opportunity for Advanced Cell Processing

    The Worldwide Opportunity for Advanced Cell Processing ‐ 31 cord blood banking companies in U.S. and 41 in EU1 ‐ ThermoGenesis’ addressable part of total CB market is 10 ‐ 15% 2 Regenerative Stem Cell Market by 2018 >$8B3 Cord Blood Market by 2016 >$3B2 Stem Cell Cord Blood Therapy Market Market Tod

  7. Slide 7: KOOL Inside: The Surrogate Play

    KOOL Inside: The Surrogate Play CEI (1) Estimated opportunity by PerkinElmer during Viacell acquisition (2) RTI Biologics, Inc. 10‐K filed March 3, 2010 Existing Partner (3) Wedbush Pacgrow initiation report on Osiris, March 4, 2009 (4) Company estimate 7 (5) Cytori Therapeutics, Inc. Investor Prese

  8. Slide 8: Cord Blood Products: AXP AutoXpress

    Cord Blood Products AXP AutoXpress™ Our Solution for Scaling Automated Precision in Isolation and Capture Collect cord blood into bag set and load into AXP 1 AS I N CL ST S BE Process up to 6 units of stem cells in centrifuge 2 Stem cell units ready for BioArchive 3 VS. VS. VS. (1) New York Blood Ce

  9. Slide 9: Cord Blood Products: BioArchive System

    Cord Blood Products BioArchive® System Stores cord blood stem cells in liquid nitrogen AS I N CL ST @ ‐196° C S BE • Precision control for accuracy & quality ‐ Only computer controlled freezing curve ‐ Robotic and optical storage and retrieval • High cell viability: ‐ Eliminates transient warming ev

  10. Slide 10: Cord Blood Stem Cells: Synergy with AXP & BA

    Cord Blood Stem Cells: Synergy with AXP & BA Cell Recovery Comparison‐CD34 cells AXP Automation Avg 97%, n=6826 BA Storage BMT 44:635; Cytotherapy 11:1101 Avg 93%; n=23 BMT 37:S310 100% 100% 93% 90% 90% 80% 80% CD34 Cell 70% Manual Process 70% Recovery Avg=83%, n=181 60% Cytotherapy 9:165 60% 50% 50

  11. Slide 11: Bone Marrow Opportunity

    Bone Marrow Opportunity Our Solution to the Challenges of Manual Processing Disposable, Automated Point‐of‐Care Solution for Rapid and Easy Bone Marrow Processing • Point‐of‐care product • High MNC recovery (>85%) • Simple and easy to use • Fast processing time (<15 min) • Flexible volume capacity •

  12. Slide 12: Worldwide Distribution Footprint - Today

    Worldwide Distribution Footprint ‐ Today — AXP, BioArchive — Res‐Q, MXP, AXP, — AXP, Res‐Q — Res‐Q, MXP — China, India, Japan BioArchive — Canada, US, — China, Hong — 14 Asian, 3 European & 5 19 European Countries, Kong African countries 11 Other Countries — Res‐Q, MXP CEI — India, Malaysia, Thailan

  13. Slide 13: China: Substantial Growth Opportunity

    China: Substantial Growth Opportunity • High regional industry concentration – “One‐child‐per‐family” policy puts premium on offspring – Total reported births of 16 million in China in 20081 – Total reported births of 4 million in the U.S. in 20101 • Significant capital investment in cord blood cent

  14. Slide 14: China: Partner Lineup

    China: Partner Lineup Significant “In‐Country” Experience 14

  15. Slide 15: Research & Development

    Research & Development Product Line Extensions & Enhancements Under Evaluation: • New disposables for the Cord Blood market New Product Design Concepts • New POC disposables: Under Evaluation • For different volumes • Modified cell compositions for new performance requirements • Tissue processing de

  16. Slide 16: Regulatory & Clinical Strategy

    Regulatory & Clinical Strategy: Unlock full therapeutic potential • Regulatory & clinical strategy: – Today: Capture safety and efficacy data set through ongoing clinical studies and evaluations • Expand 510(k) indications (Class II) • Pursue therapeutic indications through partnerships (Class III)

  17. Slide 17: ThermoGenesis Leadership

    ThermoGenesis Leadership 17

  18. Slide 18: Summary

    Summary (1) Rodman & Renshaw China Cord Corp. initiation report February 18, 2010 (2) Cord blood market opportunity assumes newborn population of 7 million in urban areas, $730 initiation fee, $73 annual storage fee, and average storage contract length of 18 years present value adjusted at 10% to $6

ThermoGenesis Holdings — Investor Presentation (June 2011) on 6ix